Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse

Benjamin W. Van Tassell, Ignacio M. Seropian, Stefano Toldo, Fadi N. Salloum, Lisa Smithson, Amit Varma, Nicholas N. Hoke, Christopher Gelwix, Vinh Chau, Antonio Abbate

Research output: Contribution to journalArticlepeer-review

50 Scopus citations

Abstract

Background: Myeloid differentiation factor 88 (MyD88) is an endogenous adaptor protein that coordinates the inflammatory response to agonists of the Toll-like receptor and interleukin-1 receptor families. This particular response is activated following myocardial ischemia and infarction and may represent a viable target for pharmacologic inhibition. The current study tested MyD88 inhibitors in a murine model of nonreperfused acute myocardial infarction (AMI). Methods: AMI was induced by permanent ligation of the left coronary artery. Adult, male, Imprinting Control Region mice were randomized to daily injections with 1 of 2 MyD88 pharmacologic inhibitors (ST2825 25 mg/kg or IMG2005 1 mg/kg), saline, or pretreatment with MyD88-targeted silencing small interfering RNA (siRNA) or scrambled nontargeted siRNA (n = 6 for each group). Echocardiography was performed at baseline and 7 days after surgery to evaluate pathologic cardiac enlargement. Results: Pharmacologic inhibition of MyD88 with ST2825 or IMG2005) and MyD88-targeted siRNA protected against left ventricular (LV) dilatation (reduced LV end-systolic and LV end-diastolic diameter) and hypertrophy. This protection occurred despite no measurable reduction in infarct size. Conclusions: Pharmacologic MyD88 inhibition protects against pathologic LV remodeling without altering infarct scar formation. MyD88 may be a viable target for pharmacologic inhibition in AMI.

Original languageEnglish
Pages (from-to)385-390
Number of pages6
JournalJournal of Cardiovascular Pharmacology
Volume55
Issue number4
DOIs
StatePublished - Apr 2010
Externally publishedYes

Keywords

  • Acute myocardial infarction
  • Heart failure
  • Inflammation
  • MyD88

Fingerprint

Dive into the research topics of 'Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse'. Together they form a unique fingerprint.

Cite this